Pharmaceutical Executive

In today's Pharmaceutical Executive Daily, a federal judge blocks RFK Jr.'s reconstituted vaccine advisory committee and halts its policy changes, a new analysis breaks down what recent Gartner predictions on AI mean for healthcare marketers, and the FDA approves Icotyde as the first oral targeted therapy for moderate-to-severe plaque psoriasis.

In today's Pharmaceutical Executive Daily, ongoing conflict in the Middle East is straining pharmaceutical supply routes to the Gulf region, Sentynl Therapeutics enters a licensing agreement with PRG-ST to advance a progerin-targeting therapy for progeria, and a new analysis examines the innovations, integration challenges, and early hurdles shaping the emerging biotech landscape.

In today's Pharmaceutical Executive Daily, a new West Health-Gallup survey finds that more than 82 million Americans have cut back on daily expenses to cover healthcare costs, the FDA expands the approved age indication for GSK's RSV vaccine Arexvy to adults aged 18 to 49 at increased risk, and a new commentary argues that agentic AI is positioned to fundamentally reshape commercial operations in life sciences.

Vincent Hennemand discusses using these types of therapies to develop treatments for autoimmune conditions.